Q-omics provides the consensus-scored NANOGP5 profile across patient tissues and cancer cell-line models. NANOGP5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NANOGP5 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, NANOGP5 RNA expression shows 11,547 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, COAD, and GBM as cancer lineages where NANOGP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NANOGP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NANOGP5 survival associations across molecular data types. NANOGP5 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NANOGP5 RNA expression–survival associations across cancer types. High NANOGP5 expression shows unfavorable associations in MESO, KIRP, ACC, UVM, TGCT and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for NANOGP5 RNA expression.
This table summarizes NANOGP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NANOGP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NANOGP5 shows lower tumor expression in THCA and higher tumor expression in COAD, STAD and PAAD. The COAD box plot shows higher NANOGP5 RNA expression in tumor versus normal tissue (log2 FC = +0.054, t-test p = .009).
This table shows molecular features associated with NANOGP5 in patient tissues and cancer cell lines. In patient samples, NANOGP5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
